ClinicalTrials.gg
RecruitingNCT07560280Updated May 1, 2026

Evaluation Criteria, Diagnostic Criteria, Surgical Indications, and Establishment of Surgical Standards for "Cerebral Tinnitus Syndrome" Caused by Internal Jugular Vein Stenosis.

An interventional study of Atlas Transverse Process Mastoidectomy with Lysis and Perfusion in Jugular Vein Anomaly (Disorder), Diagnostic Self Evaluation and Nerosurgery, sponsored by Beijing Shijitan Hospital, Capital Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Beijing Shijitan Hospital, Capital Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled May 2025, registered Apr 2026).
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
369
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

"Cerebral Tinnitus," also known as "cranial tinnitus," refers to the patient-reported perception of intracranial sounds. It often presents as "Cerebral Tinnitus Syndrome," which includes symptoms such as tinnitus with hearing loss, headaches, a heavy head sensation, blurred vision, neck and shoulder discomfort, sleep disturbances, anxiety, and depression. Due to limited awareness of cerebral tinnitus, patients frequently seek treatment across multiple facilities without success, severely impacting their and their families' lives and work.

Xunming Ji and colleagues have pointed out that cerebral tinnitus results from stenosis of the cerebral or internal jugular veins (IJVS), which impairs cerebral venous outflow and the clearance of metabolic "waste," leading to chronic metabolic damage to brain cells. Currently, studies on the diagnosis and treatment of IJVS-induced cerebral tinnitus, both domestically and internationally, are primarily case reports, lacking systematic evaluation, diagnostic, and treatment standards, which significantly impacts patient outcomes.

Our project team is the first to establish evaluation criteria, diagnostic standards, surgical indications, and surgical standards for "Cerebral Tinnitus Syndrome." In preliminary work, we performed internal jugular vein (IJV) decompression on 32 cerebral tinnitus patients, resulting in an IJV morphological improvement rate of 84.3%, a blood flow improvement rate of 75.0%, and a cerebral tinnitus syndrome improvement rate of 62.5%. To date, we have completed 88 IJV decompression surgeries, making ours the largest clinical center for such cases worldwide. We continue to refine these standards, notably introducing new intraoperative standards for IJV "release" and "high perfusion,".

To validate and further study these standards, this project plans to perform IJV decompression surgery on 107 cerebral tinnitus patients affected by IJVS. We aim to establish a cerebral tinnitus database and develop a cerebral tinnitus evaluation scale to standardize evaluation criteria, diagnostic standards, surgical indications, and surgical standards, ultimately advancing clinical diagnosis and treatment of Cerebral Tinnitus Syndrome

Read the detailed description

"Cerebral tinnitus," also known as "cranial tinnitus," is a condition where patients perceive intracranial sounds, often described as complex noises like machinery, thunder, or sirens, and may occur intermittently or persistently. Clinically, cerebral tinnitus is typically not an isolated symptom but manifests as "Cerebral Tinnitus Syndrome." In addition to cerebral tinnitus, patients frequently experience symptoms such as tinnitus with hearing loss, headaches and dizziness, head fullness or heaviness, dry eyes with blurred vision, neck and shoulder discomfort, sleep disturbances, anxiety, depression, and cognitive or memory decline.

A recent study published in the Journal of the American Medical Association: Neurology indicates that approximately 750 million people worldwide suffer from tinnitus. Due to the similarity between the symptoms of tinnitus and cerebral tinnitus, many tinnitus patients also experience cerebral tinnitus, making it difficult to distinguish between these symptoms accurately. Consequently, a substantial portion of the surveyed population may, in fact, be patients with "Cerebral Tinnitus Syndrome."

The fast-paced nature of modern life, coupled with increased stress from work and daily responsibilities, has contributed to the rising incidence of cerebral tinnitus, which has now become a common condition impacting quality of life and overall health in China. Unfortunately, effective treatments for "Cerebral Tinnitus Syndrome" remain unavailable. With limited public awareness about cerebral tinnitus, many patients seek medical help without success; conventional medications yield limited results, and patients often rely on anti-anxiety or antidepressant medications to alleviate symptoms, which severely impacts their and their families' lives and work.

Currently, the etiology of cerebral tinnitus remains unclear. Some studies suggest it may be related to alterations in blood flow within the dural sinuses or internal jugular veins (IJVs) caused by head and neck venous return obstruction or compensatory blood flow in collateral veins. Ji Xunming et al. proposed that cerebral tinnitus could result from stenosis of the cerebral or internal jugular veins, leading to impaired cerebral venous return, inadequate clearance of metabolic waste, and chronic metabolic alterations in brain cells. Specific causes may include cerebral venous thrombosis (CVT), cerebral venous sinus stenosis (CVSS), and internal jugular vein stenosis (IJVS). Unlike CVT and CVSS, IJVS is often caused by external compression, with the transverse process of the atlas and styloid process being primary contributors, affecting 40-70% of cases.

Currently, treatment approaches for cerebral tinnitus are primarily symptom-focused, lacking effective interventions targeting the underlying cause. Medications such as antidepressants and anxiolytics are mainly used to alleviate emotional symptoms, while steroids may temporarily reduce inflammatory responses associated with tinnitus, yet do not address IJVS-induced cerebral tinnitus. Audiotherapy and psychotherapy may improve psychological responses to symptoms but fail to treat the root cause. Surgical interventions may offer symptom relief in some cases with clear etiology; however, there are only a few case reports. Most available treatments are symptomatic rather than causal, underscoring the need for standardized diagnostic and treatment protocols for IJVS-induced cerebral tinnitus.

Systematic research on surgical interventions for IJVS has developed relatively recently. In 2021, Ji Xunming and colleagues summarized recent advancements in IJVS diagnosis and treatment, identifying the upper segment of the internal jugular vein as vulnerable to compression by the atlas transverse process and styloid process. For IJVS patients with distinct bony compression, surgical resection of the compressive bone has been reported to alleviate preoperative symptoms such as headaches, dizziness, and cognitive impairment. Dashti et al. reported on two IJVS patients with craniovertebral junction compression, whose symptoms improved after partial bone resection. Fritch et al. presented a case of IJVS with intracranial hypertension caused by compression from the C1 transverse process, which improved rapidly after resection. Higgins et al. examined 29 styloidectomy surgeries in IJVS patients, finding that of 23 patients undergoing the procedure for the first time without stenting, one achieved complete symptom resolution, four experienced symptom improvement, while the remaining 18 required stenting within two months. Yang et al. reported clinical improvement in 11 of 14 IJVS patients treated with condylar suboccipital lateral approach decompression. From the literature, only limited case studies and small clinical cohorts abroad focus on surgical treatment for IJVS, with no related literature from domestic studies. Additionally, there are no standardized evaluation, diagnostic, or treatment protocols for Cerebral Tinnitus Syndrome caused by IJVS.

Our team is the first globally to establish evaluation criteria, diagnostic standards, surgical indications, and surgical protocols for "Cerebral Tinnitus Syndrome" induced by IJVS. In previous work, we performed internal jugular vein (IJV) decompression on 32 patients with cerebral tinnitus, achieving an IJV morphological improvement rate of 84.3% (27/32), a blood flow improvement rate of 75.0% (24/32), and a cerebral tinnitus syndrome improvement rate of 62.5% (20/32). To date, we have completed 88 minimally invasive surgeries for IJVS-induced cerebral tinnitus, establishing the largest clinical center for these cases worldwide. We continue to refine standards, notably introducing intraoperative IJV "release" and "high perfusion" as new surgical criteria.

To further validate and expand upon these standards, this study plans to perform IJV decompression on 107 patients with IJVS-induced Cerebral Tinnitus Syndrome. Key surgical steps include: (1) standardized bony decompression, (2) soft tissue release, and (3) IJV high perfusion. Enrolled patients will undergo structured evaluation based on our established IJVS-induced Cerebral Tinnitus Syndrome assessment criteria, including "clinical symptom assessment, imaging assessment, and multidisciplinary collaborative evaluation." From these assessments, we will develop more precise diagnostic criteria and clinical classifications. Surgery will be guided by stricter surgical indications to ensure optimal patient selection, and intraoperative validation of the new techniques (standardized bony decompression, soft tissue release, and IJV high perfusion) will be conducted to achieve complete J3 segment decompression. This will set new surgical operation standards, establish a cerebral tinnitus database, create an evaluation scale for cerebral tinnitus, and examine key factors influencing clinical efficacy of IJV decompression. Through this research, we aim to enhance clinical diagnosis and treatment capabilities for IJVS-induced Cerebral Tinnitus Syndrome, relieving patient suffering and improving quality of life.

02

Conditions studied

  • Jugular Vein Anomaly (Disorder)
  • Diagnostic Self Evaluation
  • Nerosurgery
  • Assessment, Self

Keywords

  • Non-randomized Controlled Clinical Trial
03

In context

Lead sponsor

Beijing Shijitan Hospital, Capital Medical University is the lead sponsor of 15 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 75 years, with no gender restriction.
  2. Presence of one or more symptoms associated with "Cerebral Tinnitus Syndrome," with a duration of at least 3 months.
  3. Following a detailed medical history and comprehensive physical examination, other known causes of cerebral tinnitus are preliminarily excluded, with suspected internal jugular vein stenosis (IJVS) as the cause.
  4. Imaging studies (e.g., jugular ultrasound, cervical venous CT venography (CTV)) show significant stenosis in the internal jugular vein (stenosis degree ≥50%).
  5. The patient has provided and voluntarily agrees to participate in the study, with a signed informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of cranial surgery or diagnosed intracranial space-occupying lesions.
  2. Patients with severe cardiac, hepatic, or renal insufficiency, or other systemic diseases.
  3. Patients who have undergone any surgical or interventional procedures affecting jugular venous flow within the last 6 months.
  4. Patients with a history of psychiatric disorders or cognitive impairment who cannot complete study evaluations.
  5. Pregnant or breastfeeding women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
369 participants (estimated)

Study arms

  • Experimental
    Surgical Intervention Group

    Internal Jugular Vein Decompression is a surgical procedure designed to relieve stenosis or external compression of the internal jugular vein, restore normal cerebral venous outflow, and alleviate symptoms related to chronic venous congestion such as pulsatile tinnitus (tinnitus cerebri), positional headache, and visual disturbances.It can be performed via open surgical decompression (releasing surrounding soft tissue/bony compression) or endovascular intervention (balloon angioplasty/stenting) to treat significant jugular vein stenosis refractory to medical management.

    Procedure: Atlas Transverse Process Mastoidectomy with Lysis and Perfusion

Interventions

  • ProcedureAtlas Transverse Process Mastoidectomy with Lysis and Perfusion

    This surgical procedure is performed with the patient in the lateral decubitus position (affected side up), under electrophysiological monitoring of the sternocleidomastoid and trapezius muscles. A 3-4 cm straight incision is made below the mastoid tip, and the atlas transverse process is exposed via careful dissection along the anterior border of the sternocleidomastoid muscle while preserving the cervical branch of the facial nerve. Under endoscopy and microscopy, the anterolateral portion of the transverse process is thoroughly drilled using diamond burrs (4 mm and 2 mm) according to preoperative CTV measurements. After bone resection, the carotid sheath is opened to expose the internal jugular vein (IJV), and perivascular soft tissues are fully released over a width of more than 2 cm to decompress the entire J3 segment of the IJV. Subsequently, the systolic blood pressure is elevated by at least 20% above baseline and maintained for 30 minutes to achieve IJV hyperperfusion and prom

06

What researchers measure

Primary outcomes

  1. Cerebral tinnitus improvement rate at 3 months postoperatively

    Assessed by VAS score (0-10). Improvement defined as: Marked improvement: ≥30% reduction in VAS Mild improvement: 10%-30% reduction No obvious change: 0%-10% reduction Aggravation: increased VAS

    Time frame: 3 months postoperatively

Secondary outcomes

  1. Cerebral tinnitus improvement rate at 12 months postoperatively

    Assessed by VAS score (0-10) with the same improvement criteria.

    Time frame: 12 months postoperatively

  2. Improvement rate of other clinical symptoms at 3 and 12 months postoperatively

    Assessed by VAS score (0-10) with the same improvement criteria.

    Time frame: 3 and 12 months postoperatively

  3. Morphological improvement of the internal jugular vein (IJV) postoperatively

    Assessed by CTV; improvement defined by percentage increase in IJV diameter at decompressed segment.

    Time frame: 3 and 12 months postoperatively

  4. Blood flow recovery of IJV postoperatively

    Assessed by Doppler ultrasound; improvement defined by percentage increase in blood flow velocity at IJV J3 segment

    Time frame: 3 and 12 months postoperatively

  5. Safety outcomes

    Incidence of adverse events (AEs) and serious adverse events (SAEs), including intraoperative vascular/nerve injury, wound infection, neck-shoulder discomfort, and limited neck movement.

    Time frame: 3 and 12 months postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Li M, Sun Y, Chan CC, Fan C, Ji X, Meng R. Internal jugular vein stenosis associated with elongated styloid process: five case reports and literature review. BMC Neurol. 2019 Jun 4;19(1):112. doi: 10.1186/s12883-019-1344-0. PubMed 31164090 ↗

Related links

Individual participant data

Plan to share: Yes — Baseline demographic data (age, gender, body mass index, medical history). Preoperative and postoperative VAS scores for tinnitus cerebri and other clinical symptoms at 3 and 12 months. Imaging measurements: IJV diameter on CTV at the decompressed segment pre- and postoperatively. Hemodynamic data: blood flow velocity of the IJV J3 segment measured by Doppler ultrasound. Safety data: occurrence, time, and severity of adverse events and serious adverse events. Data will be shared after de-identification, without exposing participant privacy or protected health information.

Supporting information: Study protocol, Clinical study report

Time frame: The IPD and related supporting information will be made available **starting from the date of study completion**, and will remain accessible for **5 years after the end of the study**.

Access criteria: Clinical Study Report (CSR)

Data sharing details ↗ · www.bjsjth.cn

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2029, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
May 1, 2026
StartActual
May 7, 2025
Primary completionEst.
Dec 30, 2029
CompletionEst.
Dec 30, 2030
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07560280
Lead sponsor
Beijing Shijitan Hospital, Capital Medical University
Responsible party
Sponsor
First posted
May 1, 2026
Start date
May 7, 2025
Primary completion
Dec 30, 2029 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
May 1, 2026

Study contacts

Zhiqiang Hu
Contact
neuro7@163.com
86+13501378609

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion